Triple GLP-1, GIP, Glucagon

Reta is a synthetic peptide designed as a multi-receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. By engaging all three incretin-related pathways, it represents a next-generation research tool for studying metabolic regulation, appetite control, and energy expenditure.

In preclinical and clinical studies, Reta has been shown to improve glycemic control, reduce body weight, and increase energy expenditure more robustly than single- or dual-agonist compounds. Researchers often use it to investigate the synergistic effects of GLP-1, GIP, and glucagon receptor activation on insulin sensitivity, lipid metabolism, and thermogenesis. This “triple agonist” approach is of particular interest in obesity, type 2 diabetes, and metabolic syndrome research.

** This product is in lyophilized powder form and requires reconstitution solution (BAC Water) for research.